Cytori Therapeutics Inc (NASDAQ:CYTX) Raised to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Cytori Therapeutics Inc (NASDAQ:CYTX) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning. The firm currently has $1.25 price objective on the biotechnology company’s stock.
According to Zacks, “Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company’s preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. “
Other equities research analysts have also issued research reports about the company. B. Riley restated a buy rating and set a $2.30 price target on shares of Cytori Therapeutics in a research note on Monday, May 15th. Maxim Group set a $10.00 price target on Cytori Therapeutics and gave the stock a buy rating in a research note on Saturday, May 13th. Finally, ValuEngine lowered Cytori Therapeutics from a sell rating to a strong sell rating in a research note on Friday, June 2nd.
Cytori Therapeutics (NASDAQ:CYTX) traded up 1.1339% during trading on Tuesday, reaching $1.1327. 541,855 shares of the company’s stock traded hands. The company has a 50 day moving average of $1.03 and a 200 day moving average of $1.38. The firm’s market cap is $36.79 million. Cytori Therapeutics has a one year low of $0.90 and a one year high of $2.29.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.05. Cytori Therapeutics had a negative return on equity of 177.92% and a negative net margin of 491.71%. The business had revenue of $0.60 million for the quarter, compared to analyst estimates of $2.32 million. During the same quarter in the previous year, the firm earned ($0.03) earnings per share. The company’s revenue was down 53.8% on a year-over-year basis. Equities research analysts predict that Cytori Therapeutics will post ($0.90) EPS for the current year.
An institutional investor recently raised its position in Cytori Therapeutics stock. Perkins Capital Management Inc. boosted its position in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 10.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 439,679 shares of the biotechnology company’s stock after buying an additional 40,839 shares during the period. Perkins Capital Management Inc. owned approximately 1.87% of Cytori Therapeutics worth $703,000 as of its most recent SEC filing. 8.70% of the stock is currently owned by institutional investors.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.